stockrowElanco Animal Health Incorporated
ELAN Healthcare Drug Manufacturers Specialty & Generic
Elanco Animal Health Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 6.22% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +450.0%
- Free cash flow
- +35.6%
- Total debt
- −6.91%
Quarter to June 2026, against a year earlier
Follow ELAN
Alert me
Elanco Animal Health Incorporated (ELAN) Operating cash flow
Elanco Animal Health Incorporated's operating cash flow for fiscal 2025 was $560.0M, unchanged from fiscal 2024. Over the twelve months to 30 June 2026 it was $617.0M. Over the past ten years it has ranged from −$41.0M (fiscal 2020) to $560.0M (fiscal 2025) — the current reading is the highest in ten years. Elanco Animal Health Incorporated ranks 8th of 84 Drug Manufacturers Specialty & Generic companies by operating cash flow.
Operating cash flow, annual
Embed this chart
Annual newest first
| Period | Operating cash flow | Change |
|---|---|---|
| FY2025 | $560.0M | 3.51% |
| FY2024 | $541.0M | 99.63% |
| FY2023 | $271.0M | (40.04%) |
| FY2022 | $452.0M | (6.42%) |
| FY2021 | $483.0M | — |
| FY2020 | −$41.0M | — |
| FY2019 | $224.0M | (54.03%) |
| FY2018 | $487.3M | 180.38% |
| FY2017 | $173.8M | 11.48% |
| FY2016 | $155.9M | 2,262.12% |
Quarterly newest first
| Period | Operating cash flow | Change |
|---|---|---|
| Jun 2026 | $277.0M | 2,030.77% |
| Mar 2026 | $13.0M | (87.96%) |
| Dec 2025 | $108.0M | (50.68%) |
| Sep 2025 | $219.0M | (7.59%) |
| 34 more quarters | Free account |
Against its own ten years
Operating cash flow against peers
| Company | Operating cash flow |
|---|---|
| VTRS Viatris Inc. compare | $2.5B |
| NBIX Neurocrine Biosciences, Inc. compare | $1.1B |
| ELAN Elanco Animal Health Incorporated | $617.0M |
| LNTH Lantheus Holdings, Inc. compare | $409.5M |
| RDY Dr. Reddy's Laboratories Ltd compare | $313.0M |
| HIMS Hims & Hers Health, Inc. compare | $263.5M |
| ALKS Alkermes plc compare | $243.0M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $198.8M |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $180.6M |
What Operating cash flow is
Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.
Reported line item
More on ELAN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement